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Abstract
Background: Serum TSH is the target hormone by which adequate thyroid hormone supply can easily be
monitored in patients with primary hypothyroidism. It is however controversial when TSH should be measured before
thyroxine dose adjustments are made: 4 to 8 weeks are recommended. We looked at the time required to reach
stable TSH levels in hypothyroid patients.
Methods: We studied patients with newly diagnosed hypothyroidism (TSH >10 mU/l and fT4 <12.3 pmol/l).
Treatment was initiated with thyroxine 50 µg/d if there was a history of cardiac disease and 100 µg/d otherwise.
Blood pressure, weight and TSH, fT4, fT3, cystatin C and creatinine were measured once a week. Thyroxine dose
was increased by 25 µg every 8 weeks until TSH normalised.
Results: 12 patients with a mean TSH at baseline of 57.6 mU/l (range 11.3–151.8 mU/l) gave informed consent.
They were followed for 8 to 24 weeks. After adjusting for the number of observation periods for each patient, the
mean time to achieving stable TSH was 3.5 weeks (95% CI, 2.6-4.3 weeks), whereby stable TSH was defined as the
value reached on a certain replacement dose after which TSH fluctuated by no more than +/- 2 mU/l during the
remaining weeks of an 8 week observation period (median TSH at study end 4.7 mU/l).
Conclusions: TSH did not change significantly after a mean of 3.5 weeks after the introduction of thyroxine.
Dose changes can therefore be made after 4 weeks of treatment, longer periods are unnecessary.
Keywords: Hypothyroidism; Thyroid hormone replacement; Timing
Introduction
Hypothyroidism is defined as a condition in which the production
of the thyroid hormones thyroxine (T4) and triiodothyronine (T3) by
the thyroid gland is inadequate to meet peripheral tissue demand.
Primary hypothyroidism is prevalent in up to 5% of the general
population, with widely variable clinical symptoms. Thyroid failure
caused by a disease of the thyroid gland is termed primary
hypothyroidism. Primary hypothyroidism is by far the most common
cause of hypothyroidism, and occurs as a result of Hashimoto’s
thyroiditis, thyroidectomy, radiotherapy to the neck, radioiodine
thyroid ablation or medications. Decreased levels of circulating free
thyroxine and free triiodothyronine (fT4 and fT3) stimulate the
production of thyroid stimulating hormone (TSH) in the pituitary
gland to restore sufficient thyroid hormone production. An elevated
serum TSH level is the main and most sensitive laboratory
abnormality to occur in primary hypothyroidism, followed by
reductions in serum levels of fT4 and fT3.
Synthetic levothyroxine is the treatment of choice for primary
hypothyroidism. In Switzerland, two formulations are widely used,
Eltroxin and Euthyrox. The average replacement dose of levothyroxine
used in primary hypothyroidism is 1.6 µg/kg/d in young patients and
1.0 µg/kg/d in elderly subjects, who require a lower dose due to
reduced thyroid hormone metabolism [1]. Elderly patients and those
with heart disease may develop angina pectoris or arrhythmias when
started on full replacement doses, as the heart rate and cardiac
contractility improve with replacement and increase myocardial
oxygen consumption. In such patients thyroid hormone replacement
is usually commenced with 25 – 50 µg/d and increased gradually by
12.5 – 25 µg/d every 6 to 8 weeks [2].
To our knowledge, no study so far has investigated at which period
of time levothyroxine dose adjustments can be made. The rationale
behind the commonly used period of 6 to 8 weeks between dose
adjustments is that changes in serum TSH levels lag behind changes in
serum thyroid levels. Although fT4 levels increase rapidly once
thyroxine supplementation is begun, the TSH response is much slower
[3,4], in adults and neonates [5]. Recommendations for TSH screening
intervals and thyroxine dose adjustments differ considerably, with the
Swiss Pharmaceutical Compendium proposing TSH measurement and
thyroxine dose adjustments, if necessary, every 2 – 4 weeks, the joint
American Association of Clinical Endocrinologists (AACE) and
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American Thyroid Association (ATA) Guidelines every 4 – 8 weeks
[6] and the British Thyroid Association Guideline advising 8 - 12
weeks [7].
Quality of life is affected by hypothyroidism and a rapid
normalization of thyroid hormone levels is the primary aim of
treatment. Previous studies have shown that many patients receive
either excessive or insufficient supplementation [8]. On the other
hand, unnecessarily frequent monitoring incurring substantial costs,
possible risks to personal health (such as hematoma after phlebotomy)
and posing an inconvenience to the patient should be avoided. Our
aim was to better define after what length of time stable TSH levels in
patients on thyroid hormone replacement are reached to guide and
standardize treatment.
A further aspect of our study was the influence thyroid hormones
on kidney function. It is well known that hypothyroidism decreases
renal blood flow and creatinine clearance/GFR, as reflected by an
increase in creatinine levels. We wanted to observe the changes in
creatinine and cystatin C levels under the influence of thyroxine
treatment. Because cystatin C is a more reliable marker of renal action
than creatinine, we measured both creatinine and cystatin C on a
weekly basis during the study.
Materials and Methods
Patients with newly diagnosed hypothyroidism (TSH >10 mU/l and
fT4 <12.3 pmol/l) referred to the Department of Diabetes,
Endocrinology and Clinical Nutrition at the University Hospital of
Zurich were asked to participate in the study. Treatment was initiated
with thyroxine 50 µg/d if there was a history of cardiac disease and 100
µg/d otherwise. Either Eltroxin or Euthyrox were prescribed. Ethical
approval for the study was obtained in accordance with local
institutional requirements. All subjects provided written informed
consent. Data were collected between October 2010 and October 2011.
Blood pressure and weight were recorded at baseline and once a
week thereafter on the same day or, if not possible, a day earlier or
later, for 8 weeks. If TSH had not normalised after 8 weeks, the
thyroxine dose was increased by 25 µg/d and blood pressure and
weight were recorded once a week for a further 8 weeks. This cycle was
repeated until TSH had normalized or the patient withdrew from the
study.
Serum samples and laboratory assays
Blood samples were drawn once a week on the same day or, if not
possible, a day earlier or later, either in the morning or afternoon.
Patients were not fasting. Blood was taken for concentrations of TSH,
fT4, fT3, creatinine and cystatin C. TSH, fT4 and fT3 were measured
using an electrochemi-luminescence immunoassay (ECLIA) (Cobas
8000, e602 System from Roche Diagnostics). The assay for TSH had a
sensitivity to 0.005 mU/l with a TSH analytic range from 0.005-100
mU/l (adult reference range 0.16 – 4.25 mU/l). The analytical
measurement range for the fT4 assay was 0.3 - 100 pmol/l (adult
reference range 12.3–20.2 pmol/l) and the measurement range for the
fT3 assay 0.4-50 pmol/l (adult reference range 3.6 – 6.4 pmol/l).
The precision was assessed by measuring twenty replicates of
quality control samples over 20 days. The coefficient of variation
expressed as CV% was less than 2.5%, less than 4.9% and less than
3.9% for TSH, fT4 and fT3 measurements, respectively (covering a
measuring range of 1.6-9.5 mU/l, 5.8-19.3 pmol/l and 16.1-37.6 pmol/l
for TSH, fT3 and fT4 respectively).
Creatinine was measured using the Jaffe-Method (Cobas 8000, c701
System from Roche Diagnostics; coefficient of variation was 2.4% at 95
µmol/l and 2.3% at 337 µmol/l) and cystatin C by immune
nephelometry (Behring Nephelometer by Dade Behring; coefficient of
variation was 5.9% at 0.97 mg/l and 4.8% at 1.86 mg/l).
Statistical analysis
Patient ID Time (weeks) TSH (mU/I)
Patient 3 Baseline 151.8
1 51.9
2 25.7
stable TSH as per study protocol 3 4.7
4 2.7
5 1.1
6 0.9
7 0.6
8 0.7
Patient 5 Baseline 11.2
1 5.6
stable TSH as per study protocol 2 3.7
3 2.6
4 2.4
5 3.2
6 2.8
7 2.9
8 2.1
Patient 12 Baseline 29.5
1 8.2
stable TSH as per study protocol 2 4.5
3 5.5
4 3.9
5 3.5
6 3.1
7 2.7
8 2.3
Table 1: Patient examples (stable TSH levels as defined per protocol
highlighted in red)
The 12 patients were observed for a minimum of 8 weeks and a
maximum of 24 weeks (8 patients for 8 weeks, 1 patient for 16 weeks
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and 2 patients for 24 weeks). One observation period corresponded to
8 weeks, during which the thyroxine replacement dose remained
unchanged, resulting in 19 observation periods in the 12 patients. A
stable TSH was defined as the value reached on a certain replacement
dose after which TSH fluctuated by no more than +/- 2 mU/l during
the remaining weeks of the observation period. Examples visualizing
the definition of TSH stability are given in Table 1.
We performed a regression analysis to define the mean time per
patient required to reach stable TSH levels. To adjust for the different
number of observation periods per patient we calculated weighted
mean (95% confidence) values.
Paired t-tests were performed comparing patient characteristics at
baseline and study end.
To further evaluate the association between thyroid parameters
(TSH, fT4 and fT3) and kidney parameters (creatinine and cystatin C),
we performed a multilevel regression analysis to control for potential
confounders (age, weight, sex, creatinine) and to control for a
potential cluster effect (e.g. taking into account repeated
measurements per patient).
Results
TSH levels
Twelve (6 male) patients, 44.6 + 11.6 (mean + SD; range 28 - 58)
years old with a mean TSH at baseline of 59.8 mU/l (range 11.3 to
151.8 mU/l) gave informed consent and were included in the study.
Patients characteristics as well as values at baseline and at final visit are
summarised in Table 2.
Variable Baseline final visit p-value
mean (range) mean (range)
Weight (kg) 86.6 (56-126) 88.7 (55-127) 0.0095
Systolic blood pressure
(mm Hg)
124.7 (100-156) 124.8 (96-156) 0.99
Diastolic blood pressure
(mm Hg)
81.9 (66-95) 79.6 (59-111) 0.53
Pulse (bpm) 71 (54-88) 71 (55-90) 0.95
TSH (mU/I) 59.8 (11.3-151.8) 4.7 (0.21-21.1) 0.0014
fT4 (pmol/I) 6.3(1.9-10.8) 18.0 (11.0-25.2) 0.0001
fT3 (pmol/I) 2.8 (1.2-4.5) 4.7 (3.4-6.2) 0.0005
Creatinine (mol/I) 83.6 (58-176) 82.3 (58-150) 0.78
Cystatin C (mg/I) 0.75 (0.47-1.28) 0.85 (0.55-1.33) 0.0021
Table 2: Characteristics of the patients at baseline and after thyroxine
replacement therapy
Nine patients were hypothyroid secondary to autoimmune disease
(Hashimoto), 2 patients following total thyroidectomy and 1 patient
following radiotherapy to the neck. 9 patients were euthyroid by the
end of the study; the remaining 3 patients could not participate for a
further 8 weeks due to work responsibilities.
Statistical analysis including all 19 observation periods revealed a
mean time to achieving stable TSH after a thyroxine dose adjustment
of 3.5 weeks (95% CI, 2.6 - 4.3 weeks). When patients 4, 7 and 8 were
excluded, who each missed one follow-up appointment (patient 4 in
week 4, patient 7 in week 3 and patient 8 in week 5) thus making the
determination of TSH stability inaccurate, then the mean time to
achieving stable TSH levels decreased further to 2.9 weeks (95% CI, 2.0
- 3.6 weeks). Figures 1 and 2 illustrate the changes in TSH and fT4
levels over time in all 12 patients.
Figure 1: Changes in fT4 in 12 patients on thyroxine replacement
therapy (dotted lines indicate the normal range)
Figure 2: Changes in TSH in 12 patients on thyroxine replacement
therapy (dotted lines indicate the normal range.
Table 3 shows the time needed to achieve stable TSH levels among
all 12 study patients.
Weight, blood pressure and pulse rate
Comparisons of patient’s characteristics between study beginning
and end are presented in Table 2. Mean weight at baseline was 86.6 kg
(range 56-126 kg). During the study, patients gained an average of 2.1
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kg (95% CI 3.6 - 0.6 kg), which was statistically significant (p=0.009).
Systolic blood pressure increased by 0.08 mm Hg and diastolic blood
pressure decreased by 2.25 mm Hg from the beginning to the end of
the study. Blood pressure changes did not reach statistical significance,
neither did changes in pulse rate (p=>0.5 for all three parameters).
Patient Thyroxine dose (µg/d) Stable TSH as per
protocol
(mU/l)
Time needed to
reach stable TSH
(weeks)
1 50 39.8 4
75 19.6 3
100 1.2 3
2 100 10.2 3
125 7.5 2
150 1.8 2
3 100 4.7 4
4 100 8.5 7
5 100 3.7 3
6 100 3.8 3
7 100 56.6 5
125 44.2 5
175 17.8 5
8 100 4.6 7
9 100 11.2 6
10 100 24.5 6
150 2.2 2
11 100 1.7 3
12 100 4.5 3
Table 3: Time needed to achieve stable TSH levels among the 12 study
patients
Creatinine and cystatin C
Mean creatinine at baseline in the 12 patients was 84 µmol/l (range
58 – 176 µmol/l) and 83 µmol/l (range 58–150 µmol/l) at study end.
Paired t-tests showed no statistically significant change in creatinine
following thyroid hormone replacement (p = 0.7). Mean cystatin C at
baseline was 0.75 mg/l (range 0.47 – 1.28 mg/l) and 0.85 mg/l (range
0.55 – 1.33 mg/l) at study end, as illustrated in Table 2. The difference
in cystatin C between patients was not significant. Multilevel
regression analysis looking for potential effects of thyroid hormone
parameters on kidney parameters revealed that cystatin C was
significantly negatively associated with the TSH level (p=0.002), as
shown in Figure 3.
Figure 3: Negative correlation between cystatin C and TSH
Discussion
In patients with an intact hypothalamic pituitary axis, the adequacy
of thyroid hormone replacement can be assessed with TSH
measurements. There is a precise feedback loop between circulating
thyroid hormone and pituitary TSH secretion, with an exponential
TSH increase after a decrease in fT4: a decrease in fT4 by a factor of 2
leads to an increase in TSH by a factor of about 100. Because of this
sensitivity, TSH is a much better detector of minimal primary thyroid
failure than the thyroid hormones [9]. However, although the half-life
of TSH is short, the state and function of thyrotrope cells in the
pituitary lag behind changes in serum thyroid hormone levels, so that
the decrease in TSH values in response to thyroid hormone
replacement treatment is delayed. In addition, TSH exerts its action at
the transcription level and influences the hypertrophy and hyperplasia
of follicular cells. These adaptive responses result in a prolonged
elevation of TSH levels, so that the full effect of thyroid hormone
replacement on TSH does not become apparent for a number of weeks
[10,11].
To date, many guidelines for thyroid function testing and thyroid
hormone adjustment by a number of professional societies have been
published, and because of the relatively slow response time of the
pituitary, most organisations recommend repeat measurements of
TSH and adaption of thyroxine doses every 4 to 12 weeks. Once a
stable maintenance dose of thyroxine with a TSH level within the
reference range has been reached, subsequent TSH measurements are
generally only required once a year [12].
Both excessive as well as insufficient thyroxine replacement is
detrimental to a patient and may be associated with substantial
deleterious effects on quality of life. Thyroid hormone has profound
effects on the central nervous system, cardiovascular system, lipid
profile, bone metabolism and structure, energy expenditure, and body
weight. Consequently, hypothyroid patients may complain of
cognitive deficit, mood alteration and weight gain [13,14], whereas the
negative effects of excessive thyroxine replacement on bone
metabolism, cardiac function, skeletal muscle and the brain are well
known. Defining the time at which TSH measurement and thyroxine
dose adjustment during titration of thyroid replacement therapy is
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reasonable and will reliably mirror a steady state is important, and
guidelines for physicians are published at regular intervals [15-19].
The current recommended range of 4-12 weeks seems wide and varies
considerably between specialist guidelines.
This study, although small, clearly suggests that a steady state in
TSH levels after a change in thyroxine dose is reached after
approximately 3.5 weeks, with no major decreases in TSH >2 mU/l
thereafter. Therefore, measuring TSH every 4 weeks and adjusting
thyroxine dose at that time seems optimal. Knowing that dose
adjustments after 4 weeks are safe and do not bear a risk of
overtreatment will facilitate the care of hypothyroid patients, for
whom prompt normalizations of TSH levels may improve general
wellbeing. Three of our twelve patients did not continue with the study
until TSH had normalized completely due to work responsibilities.
One of these patients had a TSH level of 21 mU/l after 24 weeks of
treatment, when he asked to discontinue with the study protocol, the
other two patients had TSH levels of 7 mU/l and 9 mU/l respectively
after 8 weeks of treatment according to study protocol. The patient
with a minimum TSH of 21 mU/l had a body weight of 106 kg, and the
starting dose of 50 µg of thyroxine with dose adjustments of 25 µg
every 8 weeks will have been inadequate. TSH levels reached a nadir
within every 8 week observation period after 5, 4 and 4 weeks,
respectively, in line with the results seen among the other 11 patients.
Our study has limitations, the most major of which being the small
number of patients included and the 3 patients who failed to complete
the study according to protocol, resulting in a substantial proportion
(25%) of patients lost to follow up. However, we feel our observation
that TSH levels stabilise after approximately 3.5 weeks following a
thyroxine dose adjustment is relevant to clinical practice and warrants
confirmation in a larger study.
Patients in this study gained an average of 2.1 kg during follow-up.
Six patients gained 1-2 kg and 2 patients lost 1 kg. Four patients
(patients 1, 2, 7 and 10) experienced a significant weight gain of 4-6 kg.
This weight gain is contrary to what would be expected when
thyroxine replacement is begun. However, the 4 patients with
significant weight gain became hypothyroid following thyreoidectomy
for head and neck cancer as well as following thyroidectomy for severe
amiodarone induced hyperthyroidism. These patients’ clinical
condition improved considerably following the intervention, and
improved well-being may have contributed to the observed weight
gain. As weight gain is distressing for most patients, counteracting it
with adequate thyroid hormone treatment is an argument in favour of
thyroxine dose adjustments at the earliest feasible time.
Previous studies have shown that primary hypothyroidism is
associated with changes in kidney function and promotes endothelial
dysfunction [20-23]. Hypothyroidism decreases renal blood flow and
creatinine clearance/GFR, as reflected by an increase in creatinine
levels. Thyroid hormones have direct effects on blood vessels as well as
indirect effects mediated by IGF-1 and VEGF. IGF-1 is known to
increase forearm blood flow and creatinine clearance in humans and
as hypothyroidism leads to low levels of IGF-1, creatinine clearance is
in turn reduced. Cystatin C is considered a more reliable marker of
kidney function than creatinine, as it is produced by most nucleated
cells at a constant rate, is freely filtered by the glomeruli and
completely reabsorbed and catabolised by the tubular cells and has a
low interindividual variability. Compared with creatinine, cystatin C is
less dependent on race, and is not correlated to lean tissue mass,
gender or age. However, cystatin C is significantly affected by even
mild thyroid dysfunction, and reacts more sensitively to hypo- and
hyperthyroidism than creatinine, as the production rate of cystatin C
is influenced by thyroid hormones [24]. Previous studies have shown
that cystatin C significantly increases following thyroxine replacement
in hypothyroid patients [20], a finding we can confirm in this study.
Although creatinine did not decrease with T4 replacement therapy to a
significant extent, our results showed a statistically significant increase
in cystatin C levels following treatment (Table 2). However, the
association between cystatin C and TSH is weak and becomes
significant only when clustering (patients individual time course) is
considered. The corresponding regression model, controlling for
repeated measurements (n=135 cystatin C measurements in 12
subjects, n average=11.3 measurements) results in a significant
negative association between cystatin C and TSH. This association
remains unchanged when further controlled for age, weight, sex and
creatinine (Figure 3). In conclusion, thyroid function has to be
considered when cystatin C is used as a marker of kidney function.
We did not see a statistically significant change in diastolic blood
pressure as a marker for endothelial dysfunction following thyroid
hormone replacement therapy in this study, but a trend for an only
non-significant reduction by 2.25 mmHg (p=0.5).
In conclusion, we found that stable TSH levels, defined as no
further change in TSH levels >2 mU/l during the following weeks on
the same thyroxine replacement dose, occurred after 3.5 weeks. With
these results, measuring thyroid hormones and adapting thyroxine
doses every 4 weeks in newly diagnosed hypothyroid patients seems
reasonable.
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